HLA class I immune editing in JAK2 V617F and CALR exon 9 mutation driven myeloproliferative malignancies

被引：0
|
作者：
Ivanova, Milena [1 ]
Tsvetkova, Gergana [2 ]
Micheva, Iliana [3 ]
Lessichkova, Spaska [1 ]
Petrova, Zasmina [4 ]
Ivanova, Anela [4 ]
Madjarova, Galja [4 ]
Hadjiev, Evgueniy [2 ]
Shivarov, Velizar [5 ]
机构：
[1] Med Univ, Univ Hosp Alexandrovska, Dept Clin Immunol, Sofia, Bulgaria
[2] Med Univ, Univ Hosp Alexandrovska, Dept Clin Hematol, Sofia, Bulgaria
[3] Med Univ, Univ Hosp Sveta Marina, Clin Hematol, Varna, Bulgaria
[4] Sofia Univ St Kl Ohridski, Fac Chem & Pharm, Dept Phys Chem, Sofia, Bulgaria
[5] Med Univ Pleven, Dept Expt Res, Pleven, Bulgaria
来源：
HLA | 2023年 / 101卷 / 04期
关键词：
D O I：
暂无
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
P2
引用
收藏
页码：366 / 367
页数：2
相关论文
共 50 条
  • [21] Detection of JAK2 V617F mutation increases the diagnosis of myeloproliferative neoplasms
    Zhang, Shu-Peng
    Li, Hui
    Lai, Ren-Sheng
    ONCOLOGY LETTERS, 2015, 9 (02) : 735 - 738
  • [22] Presence of JAK2 V617F mutation in myeloproliferative and myelodysplastic syndrome patients
    Duarte, F.
    Santos, T.
    Barbosa, M.
    Santos, T.
    Goncalves, R.
    LEUKEMIA RESEARCH, 2013, 37 : S99 - S100
  • [23] Relation between JAK2 V617F mutation and chronic myeloproliferative disorders
    Xiao, Zhjian
    Zhang, Yue
    Wang, Jianxiang
    Hao, Yushu
    BLOOD, 2007, 110 (11) : 233B - 233B
  • [24] Cardiac JAK2 mutation V617F in a patient with cardiomyopathy and myeloproliferative disease
    Gattenlohner, Stefan
    Ertl, Georg
    Einsele, Hermann
    Kircher, Stefan
    Muller-Hermelink, Hans-Konrad
    Marx, Alexander
    ANNALS OF INTERNAL MEDICINE, 2008, 149 (01) : 69 - 71
  • [25] Diagnostic assays for the JAK2 V617F mutation in chronic myeloproliferative disorders
    Greiner, TC
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2006, 125 (05) : 651 - 653
  • [26] CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms
    Mikic, Tanja Belcic
    Pajic, Tadej
    Sever, Matjaz
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [27] Analysis of JAK2 V617F mutation in Tunisian patients with myeloproliferative neoplasms
    Chadi, Soumaya
    Dhaouadi, Tarak
    Sfar, Imen
    Baccouche, Hela
    Nabli, Rym
    Ben Romdhane, Neila
    Ben Abdallah, Taieb
    Gorgi, Yousr
    EUROPEAN JOURNAL OF INFLAMMATION, 2021, 19
  • [28] JAK2 V617F mutation, mesenteric vein thrombosis, and myeloproliferative disorders
    Owens, Christopher D.
    JOURNAL OF VASCULAR SURGERY, 2010, 52 (01) : 205 - 207
  • [29] JAK2 V617F mutation and VEGF levels in patients with myeloproliferative disorders
    Bourantas, L.
    Chatzikyriakidou, A.
    Panteli, K.
    Bai, M.
    Bourantas, D. K.
    Tsiara, St.
    Georgiou, I.
    Bourantas, K. L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 547 - 548
  • [30] ESSENTIAL THROMBOCYTHEMIA WITH JAK2 V617F OR CALR MUTATION: TWO DIFFERENT PHENOTYPES
    Vilches Moreno, A. S.
    Guerrero Fernandez, L.
    Gonzalez Medina, J.
    Ayala Diaz, R.
    Martinez Lopez, J.
    Monteagudo Saiz, D.
    Andreu Costa, M. A.
    Robles Marinas, V.
    HAEMATOLOGICA, 2016, 101 : 811 - 811
12345